Cargando…

Autologous humanized mouse models of iPSC-derived tumors enable characterization and modulation of cancer-immune cell interactions

Modeling the tumor-immune cell interactions in humanized mice is complex and limits drug development. Here, we generated easily accessible tumor models by transforming either primary skin fibroblasts or induced pluripotent stem cell-derived cell lines injected in immune-deficient mice reconstituted...

Descripción completa

Detalles Bibliográficos
Autores principales: Moquin-Beaudry, Gaël, Benabdallah, Basma, Maggiorani, Damien, Le, Oanh, Li, Yuanyi, Colas, Chloé, Raggi, Claudia, Ellezam, Benjamin, M'Callum, Marie-Agnès, Dal Soglio, Dorothée, Guimond, Jean V., Paganelli, Massimiliano, Haddad, Elie, Beauséjour, Christian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9017190/
https://www.ncbi.nlm.nih.gov/pubmed/35474871
http://dx.doi.org/10.1016/j.crmeth.2021.100153
Descripción
Sumario:Modeling the tumor-immune cell interactions in humanized mice is complex and limits drug development. Here, we generated easily accessible tumor models by transforming either primary skin fibroblasts or induced pluripotent stem cell-derived cell lines injected in immune-deficient mice reconstituted with human autologous immune cells. Our results showed that fibroblastic, hepatic, or neural tumors were all efficiently infiltrated and partially or totally rejected by autologous immune cells in humanized mice. Characterization of tumor-immune infiltrates revealed high expression levels of the dysfunction markers Tim3 and PD-1 in T cells and an enrichment in regulatory T cells, suggesting rapid establishment of immunomodulatory phenotypes. Inhibition of PD-1 by Nivolumab in humanized mice resulted in increased immune cell infiltration and a slight decrease in tumor growth. We expect that these versatile and accessible cancer models will facilitate preclinical studies and the evaluation of autologous cancer immunotherapies across a range of different tumor cell types.